Poseida Thera

$2.02 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Poseida Thera

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.

Stock Analysis

last close $2
1-mo return -44.9%
3-mo return -49.1%
avg daily vol. 273.82T
52-week high 11.1
52-week low 1.83
market cap. $137M
forward pe -
annual div. -
roe -87.4%
ltg forecast -
dividend yield -
annual rev. $33M
inst own. 43.5%

Subscribe now for daily local and international financial news